(PharmaNewsWire.Com, February 14, 2019 ) According to the new market research report "Superdisintegrants Market by Product (Modified Starch, Modified Cellulose, Crospovidone, Ion Exchange Resin), Formulation (Tablet, Capsules), Therapeutic Area (Gastrointestinal, Cardiovascular, Neurology, Oncology, Hematology) - Global Forecast to 2023", published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities in North America, Europe, Asia-Pacific, and the Rest of the world (RoW).
The global superdisintegrants market is projected to reach USD 536.5 million by 2023 from USD 366.4 billion in 2018, at a CAGR of 7.9%. Factors contributing to the growth of this market include the increasing adoption of orally disintegrating tablets, growing generics market, and the emergence of new superdisintegrants for the pharmaceutical industry. The shifting focus of pharmaceutical manufacturing to emerging markets and the growth of the overall pharmaceutical sector in these markets present significant opportunities for the superdisintegrants market growth.
The report analyzes the global superdisintegrants market by type, formulation, therapeutic area, and region. By type, the synthetic superdisintegrants segment accounted for the largest share of the market in 2017. The large share of this segment can be attributed to the extensive consumption of these superdisintegrants in various pharmaceutical drug formulations due to the advantages offered such as effectiveness at lower concentrations as compared to starch and a lesser effect on the compressibility and flowability of the dosage form.
Based on formulation, the tablets segment accounted for the larger share of the global superdisintegrants market in 2017. The large share of this segment can be attributed to tablets being the most widely used dosage forms due to the benefits offered such as stability, low manufacturing cost (as compared to other dosage forms), easy product identification, and compactness, along with the increasing focus on orally disintegrating tablets and fast-dissolving tablets.
Based on therapeutic area, the neurological diseases segment is expected to register the highest CAGR during the forecast period. This can be attributed to the increasing incidences of neurological disorders at the global level along with the growing demand for effective therapies.
Key Players: The prominent players in the global superdisintegrants market are Ashland Inc. (US), BASF SE (Germany), DowDuPont (US), JRS Pharma (Germany), DFE Pharma (Germany), Roquette (France), Asahi Kasei Corporation (Japan), Merck KGaA (Germany), Corel Pharma Chem (India), and Avantor Performance Materials, LLC (US). These players are increasingly undertaking mergers and acquisitions, and product launches to develop and introduce new technologies and products in the market.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
